20th Jun 2007 12:30
20 June 2007
Shire plc AGM - 2007
Results of the Annual General Meeting
Shire plc held its Annual General Meeting today. All resolutions were put to the meeting and approved on a show of hands. The proxy votes received for the meeting are set out below:
For* Against Abstentions 1. To receive the 447,172,037 618,289 344,753 Companys' accounts for the year ended 31 (99.86%) (0.14%) December 2006 2. To re-elect Dr James 438,104,602 9,521,491 508,986 Henry Cavanaugh as a director (97.87%) (2.13%) 3. To re-elect Dr Barry 442,879,006 4,746,232 509,841 John Price as a director (98.94%) (1.06%) 4. To elect Ms Kathleen 445,691,229 1,829,400 614,450 Anne Nealon as a director (99.59%) (0.41%) 5. To elect Dr Jeffrey 446,606,331 722,660 806,088 Marc Leiden as a director (99.84%) (0.16%) 6. To re-elect Mr Matthew 443,368,069 3,263,625 1,503,385 William Emmens as a director (99.27%) (0.73%) 7. To re-elect Mr David 445,342,529 1,866,620 925,930 John Kappler as a director (99.58%) (0.42%) 8. To re-elect Mr Patrick 445,769,759 1,689,983 675,337 Jean Marc Langlois as a director (99.62%) (0.38%) 9. To re-appoint Deloitte 443,403,135 3,642,175 1,089,769 & Touche LLP as Auditors (99.19%) (0.81%) 10. To authorise the Audit 445,398,735 2,649,952 86,392 Committee to determine the remuneration of the (99.41%) (0.59%) Auditors 11. To approve the 409,534,456 34,837,916 3,762,707 Directors' Remuneration Report (92.16%) (7.84%) 12. To authorise the 438,600,896 8,651,326 882,857 allotment of shares (98.07%) (1.93%) 13. To authorise the 445,430,893 2,019,318 684,868 disapplication of pre-emption rights (99.55%) (0.45%) 14. To authorise market 447,306,882 60,523 767,674 purchases (99.99%) (0.01%) 15. To authorise donations 442,515,165 3,095,982 2,523,932 to EU political organisations and EU (99.31%) (0.69%) political expenditure 16. To approve the rules of 443,650,279 3,168,294 1,316,506 the 2007 Shire plc Employee Stock Purchase (99.29%) (0.71%) Plan
* These figures include discretionary votes
** Abstentions are not counted in the proportion of votes "for" or "against"
T May
Company Secretary
For further information please contact:
Investor Relations Clĩa Rosenfeld (Rest of the World) +44 1256 894 160 Eric Rojas (North America) +1 484 595 8252 Notes to editorsSHIRE PLC
Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results.
Shire's focused strategy is to develop and market products for specialty physicians. Shire's in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.
For further information on Shire, please visit the Company's website: www.shire.com.
2Hampshire International Business Park Chineham Basingstoke Hampshire RG24 8EP United Kingdom Tel +44 (0)1256 894000 Fax +44 (0)1256 894708 www.shire.com Press Release
Registered in England 5492592Registered Office as above
SHIRE PLCRelated Shares:
Shire